Search results for "rheumatology"

showing 10 items of 851 documents

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

Equal distribution of T-lymphocyte subpopulations in thymus and spleen cells of NZB and BALB/c mice

1984

NZB mice develop an autoimmune disease of unknown etiology. Since the detection of immunoregulatory T-cells it has been speculated that disbalances of these cells may be important in the course of the NZB disease. By utilization of monoclonal antibody defining immunoregulatory Lyt subsets and a FACS IV system we investigated whether differences in the number and/or marker densities of given subsets exist between NZB and the normal reference strain BALB/c. Newborn animals and animals up to 60 weeks of age were tested. No significant difference in the percentages nor in the marker densities of theta+, Lyt 1+, and Lyt 2+ cells was observed at any age or sex, neither in spleen nor in thymus. It…

Agingmedicine.medical_specialtymedicine.drug_classT-LymphocytesImmunologychemical and pharmacologic phenomenaSpleenThymus GlandMonoclonal antibodyBALB/cLeukocyte CountMiceRheumatologyInternal medicinemedicineAnimalsImmunology and AllergyDistribution (pharmacology)Autoimmune diseaseMice Inbred BALB CMice Inbred NZBbiologySignificant differenceT lymphocyteFlow Cytometrybiology.organism_classificationmedicine.diseaseRheumatologymedicine.anatomical_structureImmunologySpleenRheumatology International
researchProduct

Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis.

2012

Item does not contain fulltext OBJECTIVE: Prostaglandin D2 (PGD2) may exert proinflammatory or antiinflammatory effects in different biologic systems. Although this prostanoid and the enzymes responsible for its synthesis are up-regulated by interleukin-1beta (IL-1beta) in human chondrocytes in vitro, the role of PGD2 in arthritis remains unclear. This study was undertaken to investigate the role of PGD2 in the inflammatory response and in joint destruction during the development of collagen-induced arthritis (CIA) in mice. METHODS: PGD2 and cytokine levels in mice with CIA were determined by enzyme-linked immunosorbent assay. Expression of hematopoietic PGD synthase (h-PGDS), lipocalin-typ…

Agonistmusculoskeletal diseasesmedicine.medical_specialtyIndolesmedicine.drug_classmedicine.medical_treatmentChemokine CXCL1ImmunologyInterleukin-1betaReceptors ProstaglandinArthritisInflammationProinflammatory cytokinechemistry.chemical_compoundMiceRheumatologyBone MarrowInternal medicinemedicineImmunology and AllergyAnimalsPharmacology (medical)Receptors ImmunologicReceptorintegumentary systembusiness.industryProstaglandin D2Hydantoinsmedicine.diseaseArthritis ExperimentalLipocalinsHindlimbInterleukin-10Up-RegulationIntramolecular OxidoreductasesInterleukin 10CytokineEndocrinologychemistryMice Inbred DBACytokinesJointslipids (amino acids peptides and proteins)Prostaglandin D2Immune Regulation Auto-immunity transplantation and immunotherapy [NCMLS 2]medicine.symptombusiness
researchProduct

Developments in pediatrics in 2020: choices in allergy, autoinflammatory disorders, critical care, endocrinology, genetics, infectious diseases, micr…

2021

AbstractIn this article, we describe the advances in the field of pediatrics that have been published in the Italian Journal of Pediatrics in 2020. We report progresses in understanding allergy, autoinflammatory disorders, critical care, endocrinology, genetics, infectious diseases, microbiota, neonatology, neurology, nutrition, orthopedics, respiratory tract illnesses, rheumatology in childhood.

Allergyrespiratory tract illnessesRespiratory Tract DiseasesrheumatologyChild Nutrition SciencesReviewinfectious diseasesPediatricsneonatologyRJ1-570endocrinologyRare DiseasesHypersensitivitymicrobiotaortopedicsHumansgeneticsInfectious Disease MedicineAllergy Autoinflammatory disorders Child Nutrition Sciences COVID-19 Critical care Endocrinology Gastrointestinal Microbiome Genetics Hypersensitivity Infectious Disease Medicine Infectious diseases Microbiota Neonatology Neurology Nutrition Orthopedics Rare Diseases Respiratory Tract Diseases RheumatologyneurologyCOVID-19General MedicineGastrointestinal Microbiomecritical careOrthopedicsnutritionautoinflammatory disordersItalian Journal of Pediatrics
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Brief Report: Intestinal dysbiosis in ankylosing spondylitis

2015

Objective Ankylosing spondylitis (AS) is a common, highly heritable immune-mediated arthropathy that occurs in genetically susceptible individuals exposed to an unknown but likely ubiquitous environmental trigger. There is a close relationship between the gut and spondyloarthritis, as exemplified in patients with reactive arthritis, in whom a typically self-limiting arthropathy follows either a gastrointestinal or urogenital infection. Microbial involvement in AS has been suggested; however, no definitive link has been established. The aim of this study was to determine whether the gut in patients with AS carries a distinct microbial signature compared with that in the gut of healthy contro…

Ankylosing spondylitiAnkylosing spondylitis; Community profiling; Intestinal microbiome; Immunology; Immunology and Allergy; RheumatologyRheumatologyImmunologyCommunity profilingImmunology and AllergyIntestinal microbiome
researchProduct

Response to: 'IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis' by Neerinc…

2014

We read with interest the study by Neerinckx et al 1 addressing the expression of interleukin (IL)-23p19 and of autophagy genes in the synovium and in the peripheral blood mononuclear cells of patients with ankylosing spondylitis (AS). Differently from our observation in the gut,2 the authors failed to demonstrate any significant increase by RT-PCR in the expression of synovium autophagy-related genes (ATG16L1, IRGM, MAP1LC3A, ATG5, HSPA8 and HSP90AA1) together with no significant overexpression of IL-23p19 compared with disease and healthy controls. We have previously demonstrated by immunohistochemistry that in the …

Ankylosing spondylitisIL-23 Ankylosing Spondylitisbusiness.industryAnkylosing SpondylitisImmunologyATG5AutophagyInterleukinmedicine.diseasePeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyRheumatologyIL-23ImmunologyIRGMmedicineInterleukin 23Immunology and AllergybusinessATG16L1
researchProduct

Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis

2017

Objective: To investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS). Methods: Patients who met the modified New York criteria for AS were recruited for the study. Healthy volunteers, rheumatoid arthritis patients, and osteoarthritis patients were included as controls. Based on the annual rate of increase in modified Stoke AS Spine Score (mSASSS), AS patients were classified as progressors or nonprogressors. MIF levels in serum and synovial fluid were quantitated by enzyme-linked immunosorbent assay. Predictors of AS progression were evaluated using logistic regression analysis. Immunohistochemical analysis of ileal tissue was…

AnkylosingAdultMaleLogistic ModelMacrophageImmunologyEnzyme-Linked Immunosorbent AssayIntramolecular OxidoreductasePredictive Value of TestMonocyteSeverity of Illness IndexCalcificationCalcification PhysiologicPaneth CellRheumatologySynovial Fluidotorhinolaryngologic diseasesImmunology and AllergySpondylitis AnkylosingPhysiologicSpondylitiMacrophage Migration-Inhibitory FactorTumor Necrosis Factor-alphaOsteoblastB-LymphocyteHistocompatibility Antigens Class IIMiddle AgedSpineAntigens Differentiation B-LymphocyteSettore MED/16 - ReumatologiaAntigenDifferentiationDisease ProgressionFemaleCase-Control StudieHuman
researchProduct

Heart Valve Abnormalities in Systemic Sclerosis Patients; A Multicenter Cohort Study and Review of the Literature

2020

Background Systemic sclerosis (SSc) is a chronic autoimmune disease that is characterized by vasculopathy and fibrosis of the skin and visceral organs. Heart valve diseases are poorly described and generally not considered typical of SSc. We aimed to describe valvular abnormalities in a multicenter cohort of SSc patients and to investigate their correlation with SSc features. Methods We recruited 118 consecutive SSc patients (male/female, 14/104; mean age, 55.2 ± 12.1 years) in 3 rheumatology centers in Sicily, Italy, from January to October 2019. Results Mitral and tricuspid valve insufficiency was found in 85% and 91% of patients, respectively; regurgitations were generally mild and never…

Aortic valveAdultMalemedicine.medical_specialtyHeart Valve DiseasesTricuspid stenosisSclerodermaCohort Studies03 medical and health sciences0302 clinical medicineRheumatologyTricuspid Valve InsufficiencyMitralInternal medicineMedicineHumansMulticenter Studies as Topiccardiovascular diseases030212 general & internal medicineHeart valveAortic valveskin and connective tissue diseasesAged030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industrySystemicMitral Valve InsufficiencyMiddle Agedmedicine.diseaseValvular diseaseHeart ValvesRheumatologyTricuspid Valve InsufficiencyStenosismedicine.anatomical_structurePulmonary valvecardiovascular systemCardiologySystemic sclerosisFemalebusinessTricuspidCohort study
researchProduct

AB0564 HEART VALVULAR ALTERATIONS IN A MULTICENTRE ITALIAN COHORT OF SSC PATIENTS

2020

Background:systemic sclerosis (SSc) in a chronic autoimmune disease characterized by endothelial dysfunction, diffuse microangiopathy, and fibrosis of skin and visceral organs. Typical cardiac involvement may includes microvascular ischemia, contraction band necrosis, and patchy fibrosis, leading mainly to arrythmias and conduction defects, diastolic dysfunction, or right ventricular failure (secondary to pulmonary arterial hypertension) [1]. Valvular diseases are poorly described and generally not considered a typical sign of SSc [2-4].Objectives:we aimed to describe valvular alterations in a multicentre cohort of SSc patients.Methods:we consecutively recruited 118 SSc patients (M/F: 14/10…

Aortic valveMitral regurgitationmedicine.medical_specialtyTricuspid valvebusiness.industryImmunologyTricuspid insufficiencymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologySclerodermamedicine.anatomical_structureRheumatologyPulmonary valveMitral valveInternal medicinemedicineCardiologyImmunology and AllergyTransthoracic echocardiogrambusinessAnnals of the Rheumatic Diseases
researchProduct